The purpose of this study is to investigate the mechanism of statin-related myopathy by evaluating muscle samples before and after statin exposure.
Statins have been proven to reduce cardiovascular events and mortality in large clinical trials but remain underutilized partly due to the associated myopathy. Severe reactions manifested as rhabdomyolysis are rare but myalgia is commonly noted in clinical practice. The pathophysiology of these events remains obscure. Previous studies suggest that statins block the downstream products (such as cellular signaling molecules) of the mevalonate pathway needed for normal muscle function. Other studies show that statins are associated with gene expressions involved in muscle damage such as atrogin-1. We will quantify these entities pre and post statin therapy to better understand these reactions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
simvastatin 80 mg PO daily for one to eight months.
Scripps-Mercy Hospital
San Diego, California, United States
Atrogin-1 expression.
Time frame: One to eight months.
Intramuscular Ras level.
Time frame: One to eight months.
Intramuscular Coenzyme Q10 level.
Time frame: One to eight months.
Intramuscular mitochondrial to nuclear DNA ratio.
Time frame: One to eight months.
Intramuscular geranylgeranylpyrophosphate.
Time frame: One to eight months.
PPAR-gamma coactivator-1-alpha expression.
Time frame: One to eight months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.